BIO Letter to USTR Ambassador Tai and Commerce Secretary Gino Raimondo on Indo-Pacific Economic Framework
March 11, 2022
The Biotechnology Innovation Organization (BIO) welcomes the White House announcement of the Indo-Pacific Strategy and supports efforts to reaffirm U.S. economic engagement with trading partner countries in the Indo-Pacific region and build an Indo-Pacific Economic Framework (IPEF). This effort has the potential to contribute to the robustness of the global economy by promoting sustainable economic development, thereby creating improved opportunities and benefits for workers around the world and addressing climate threats globally. In addition, commitments promoting trade, data flows, sustainability and climate, supply chains, and innovation are critical to growing the competitiveness of American biotech companies.
Download Full Comments Below
BIO Letter to Amb. Tai and Sec. Raimondo - Indo-Pacific Economic Framework
BIO and the American Seed Trade Association submitted comments on USDA-APHIS' proposed exemptions of five types of genetic modifications a plant can contain and be exempt from regulations for the movement of organisms modified or produced through…
BIO and BIO members are urging lawmakers to enact a short-term extension of the MCM-PRV program while Congress is waiting to address a full reauthorization with PAHPA.
The Biotechnology Innovation Organization (BIO) welcomes the White House announcement of the Indo-Pacific Strategy and supports efforts to reaffirm U.S. economic engagement with trading partner countries in the Indo-Pacific region and build an Indo-Pacific Economic Framework (IPEF). This effort has the potential to contribute to the robustness of the global economy by promoting sustainable economic development, thereby creating improved opportunities and benefits for workers around the world and addressing climate threats globally. In addition, commitments promoting trade, data flows, sustainability and climate, supply chains, and innovation are critical to growing the competitiveness of American biotech companies.